Arcus Biosciences, Inc.
Symbol: RCUS (NYSE)
17.55
▲ (4.56%) 0.765
Company Description:
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Key Stats
- Today's Open: $16.99
- Today's High: $17.865
- Today's Low: $16.6
- Today's Volume: 539.71K
- Yesterday Close: $16.78
- Yesterday High: $16.975
- Yesterday Low: $16.41
- Yesterday Volume: 1.04M
- Last Min Volume: 150
- Last Min High: $17.545
- Last Min Low: $17.545
- Last Min VWAP: $17.545
Company Profile
- Name: Arcus Biosciences, Inc.
- Website: https://www.arcusbio.com
- Listed Date: 2018-03-15
- Location: HAYWARD, CA
- Market Status: Active
- CIK Number: 0001724521
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.79B
- Round Lot: 100
- Outstanding Shares: 106.43M
- Asset Type: CS
RECENT FILINGS FOR RCUS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-14 | 8-K | View |
| 2025-10-08 | 4 | View |
| 2025-10-06 | 144 | View |
| 2025-10-06 | 8-K | View |
| 2025-09-30 | 4 | View |
| 2025-09-29 | 144 | View |
| 2025-09-05 | 4 | View |
| 2025-09-05 | 144 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-15 | SCHEDULE 13D/A | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-02 | 8-K | View |
Latest News on RCUS